Skip to main content

Advertisement

SpringerLink
Log in

When Is Prophylactic Thyroidectomy Indicated for Patients with the RET Codon 609 Mutation?

  • Endocrine Tumors
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Mutations in the RET proto-oncogene cause multiple endocrine neoplasia type 2A (MEN2A), and prophylactic thyroidectomy has generally been recommended before the age of 5 years. Patients with codon 609 mutations develop MTC at a later age and therefore the timing of prophylactic thyroidectomy is less clear. We report a three-generation family with C609Y RET mutation where members having prophylactic or therapeutic thyroidectomy call the current recommendations for age at thyroidectomy into question.

Methods

Sixteen family members underwent thyroidectomy, for which clinical, laboratory, and pathological data were analyzed. A literature review of RET codon 609 mutations was carried out.

Results

Data were collected from 16 patients from this 38-member kindred. None of these affected members had pheochromocytoma, and one had a parathyroid adenoma. Nine of 16 patients had MTC (mean age 44.7 years, range 29–59 years) and elevated basal calcitonin levels; 6 of these 9 had lymph node metastases. Two patients had C-cell hyperplasia (CCH) at ages 18 and 37 years, and five patients had normal thyroid pathology (mean age 16 years, range 5–37 years). In the literature, a family with C609Y mutation was reported, with 15 members having MTC (mean age 42 years, range 21–59 years), and 6 with CCH (mean age 24 years, range 15–37 years).

Conclusion

The youngest patient with C609Y RET mutation and MTC was 21 years old, and the youngest patient with CCH was 15 years old at diagnosis. These data suggest that patients with RET C609Y mutations can delay thyroidectomy until 10–15 years of age, with annual calcitonin screening prior to thyroidectomy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Howe JR, Norton JA, Wells SA, Jr. Prevalence of pheochromocytoma and hyperparathyroidism in multiple endocrine neoplasia type 2A: results of long-term follow-up. Surgery. 1993;114:1070–7.

    PubMed  CAS  Google Scholar 

  2. Moore SW, Zaagl MG. Multiple endocrine neoplasia syndromes, children, Hirschsprung’s disease and RET. Pediatr Surg Int. 2008;24:521–30.

    Article  PubMed  CAS  Google Scholar 

  3. Donis-Keller H, Dou S, Chi D, et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet. 1993;2:851–6.

    Article  PubMed  CAS  Google Scholar 

  4. Mulligan LM, Kwok JB, Healey CS, et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature. 1993;363:458–60.

    Article  PubMed  CAS  Google Scholar 

  5. Iwashita T, Kato M, Murakami H, et al. Biological and biochemical properties of Ret with kinase domain mutations identified in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinoma. Oncogene. 1999;18:3919–22.

    Article  PubMed  CAS  Google Scholar 

  6. Ito S, Iwashita T, Asai N, et al. Biological properties of Ret with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirschsprung’s disease phenotype. Cancer Res. 1997;57:2870–2.

    PubMed  CAS  Google Scholar 

  7. Ponder BA, Smith D. The MEN II syndromes and the role of the ret proto-oncogene. Adv Cancer Res. 1996;70:179–222.

    Article  PubMed  CAS  Google Scholar 

  8. Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001;86:5658–71.

    Article  PubMed  CAS  Google Scholar 

  9. Eng C, Clayton D, Schuffenecker I, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA. 1996;276:1575–9.

    Article  PubMed  CAS  Google Scholar 

  10. Mulligan LM, Eng C, Attie T, et al. Diverse phenotypes associated with exon 10 mutations of the RET proto-oncogene. Hum Mol Genet. 1994;3:2163–7.

    Article  PubMed  CAS  Google Scholar 

  11. Quayle FJ, Fialkowski EA, Benveniste R, Moley JF. Pheochromocytoma penetrance varies by RET mutation in MEN 2A. Surgery. 2007;142:800–5;discussion 805 e1.

    Google Scholar 

  12. Zaydfudim V, Stover DG, Caro SW, Phay JE. Presentation of a medullary endocrine neoplasia 2A kindred with Cushing’s syndrome. Am Surg. 2008;74:659–61.

    PubMed  Google Scholar 

  13. Yip L, Cote GJ, Shapiro SE, et al. Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship. Arch Surg. 2003;138:409–16;discussion 416.

    Google Scholar 

  14. Machens A, Brauckhoff M, Holzhausen HJ, et al. Codon-specific development of pheochromocytoma in multiple endocrine neoplasia type 2. J Clin Endocrinol Metab. 2005;90:3999–4003.

    Article  PubMed  CAS  Google Scholar 

  15. Decker RA, Peacock ML. Occurrence of MEN 2a in familial Hirschsprung’s disease: a new indication for genetic testing of the RET proto-oncogene. J Pediatr Surg. 1998;33:207–14.

    Article  PubMed  CAS  Google Scholar 

  16. Decker RA, Peacock ML, Watson P. Hirschsprung disease in MEN 2A: increased spectrum of RET exon 10 genotypes and strong genotype-phenotype correlation. Hum Mol Genet. 1998;7:129–34.

    Article  PubMed  CAS  Google Scholar 

  17. Halling KC, Bufill JA, Cotter M, et al. Age-related disease penetrance in a large medullary thyroid cancer family with a codon 609 RET gene mutation. Mol Diagn. 1997;2:277–86.

    Article  PubMed  Google Scholar 

  18. Munnes M, Fanaei S, Schmitz B, et al. Familial form of Hirschsprung disease: nucleotide sequence studies reveal point mutations in the RET proto-oncogene in two of six families but not in other candidate genes. Am J Med Genet. 2000;94:19–27.

    Article  PubMed  CAS  Google Scholar 

  19. Elisei R, Romei C, Cosci B, et al. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. J Clin Endocrinol Metab. 2007;92:4725–9.

    Article  PubMed  CAS  Google Scholar 

  20. Koch CA, Brouwers FM, Vortmeyer AO, et al. Somatic VHL gene alterations in MEN2-associated medullary thyroid carcinoma. BMC Cancer. 2006;6:131.

    Google Scholar 

  21. Zakrzewska A, Makowska AM, Bar-Andziak E. [Late onset of medullary thyroid carcinoma with bilateral adrenal pheochromocytomas in the case of patient with MEN 2]. Pol Merkur Lekarski. 2004;17:633–7.

    PubMed  Google Scholar 

  22. Simon S, Pavel M, Hensen J, et al. Multiple endocrine neoplasia 2A syndrome: surgical management. J Pediatr Surg. 2002;37:897–900.

    Article  PubMed  CAS  Google Scholar 

  23. Fitze G, Schreiber M, Hohenberger W, et al. Interaction of RET proto-oncogene codon 609 germline mutations with RET haplotypes characterized by c.135G > A alleles modifying MEN 2A or HSCR phenotypes. Am J Med Genet A. 2004;129A:323–5.

    Article  PubMed  Google Scholar 

  24. Kinlaw WB, Scott SM, Maue RA, et al. Multiple endocrine neoplasia 2A due to a unique C609S RET mutation presents with pheochromocytoma and reduced penetrance of medullary thyroid carcinoma. Clin Endocrinol (Oxf). 2005;63:676–82.

    Article  CAS  Google Scholar 

  25. Patocs A, Karadi E, Toth M, et al. Clinical and biochemical features of sporadic and hereditary phaeochromocytomas: an analysis of 41 cases investigated in a single endocrine centre. Eur J Cancer Prev. 2004;13:403–9.

    Article  PubMed  CAS  Google Scholar 

  26. Klein I, Esik O, Homolya V, et al. Molecular genetic diagnostic program of multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma syndromes in Hungary. J Endocrinol. 2001;170:661–6.

    Article  PubMed  CAS  Google Scholar 

  27. Igaz P, Patocs A, Racz K, et al. Occurrence of pheochromocytoma in a MEN2A family with codon 609 mutation of the RET proto-oncogene. J Clin Endocrinol Metab. 2002;87:2994.

    Google Scholar 

  28. Kusafuka T, Wang Y, Puri P. Novel mutations of the endothelin-B receptor gene in isolated patients with Hirschsprung’s disease. Hum Mol Genet. 1996;5:347–9.

    Article  PubMed  CAS  Google Scholar 

  29. Pingault V, Bondurand N, Kuhlbrodt K, et al. SOX10 mutations in patients with Waardenburg–Hirschsprung disease. Nat Genet. 1998;18:171–3.

    Article  PubMed  CAS  Google Scholar 

  30. Toledo SP, dos Santos MA, Toledo Rde A, Lourenco Junior DM. Impact of RET proto-oncogene analysis on the clinical management of multiple endocrine neoplasia type 2. Clinics. 2006;61:59–70.

    Article  PubMed  Google Scholar 

  31. Sosa JA, Tuggle CT, Wang TS, et al. Clinical and economic outcomes of thyroid and parathyroid surgery in children. J Clin Endocrinol Metab. 2008;93:3058–65.

    Article  PubMed  CAS  Google Scholar 

  32. Papi G, Corrado S, Pomponi MG, et al. Concurrent lymph node metastases of medullary and papillary thyroid carcinoma in a case with RET oncogene germline mutation. Endocr Pathol. 2003;14:269–76.

    Article  PubMed  CAS  Google Scholar 

  33. Melillo RM, Cirafici AM, De Falco V, et al. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma. Am J Pathol. 2004;165:511–21.

    PubMed  CAS  Google Scholar 

  34. Rossi S, Fugazzola L, De Pasquale L, et al. Medullary and papillary carcinoma of the thyroid gland occurring as a collision tumour: report of three cases with molecular analysis and review of the literature. Endocr Relat Cancer. 2005;12:281–9.

    Article  PubMed  CAS  Google Scholar 

  35. Fazioli F, Piccinini G, Appolloni G, et al. A new germline point mutation in Ret exon 8 (cys515ser) in a family with medullary thyroid carcinoma. Thyroid. 2008;18:775–82.

    Article  PubMed  CAS  Google Scholar 

  36. Brauckhoff M, Gimm O, Hinze R, et al. Papillary thyroid carcinoma in patients with RET proto-oncogene germline mutation. Thyroid. 2002;12:557–61.

    Article  PubMed  CAS  Google Scholar 

  37. Feldman GL, Edmonds MW, Ainsworth PJ, et al. Variable expressivity of familial medullary thyroid carcinoma (FMTC) due to a RET V804 M (GTG → ATG) mutation. Surgery. 2000;128:93–8.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Division of Surgical Oncology and Endocrine Surgery, University of Iowa College of Medicine, Iowa City, IA, USA

    Daniel Calva MD, Geeta Lal MD, Sonia Sugg MD, Ronald J. Weigel MD & James R. Howe MD

  2. Department of Medicine, Division of Endocrinology and Metabolism, University of Iowa College of Medicine, Iowa City, IA, USA

    Thomas M. O’Dorisio MD

  3. Department of Pediatrics, Division of Hematology, Oncology, Immunology, and Rheumatology, University of Iowa College of Medicine, Iowa City, IA, USA

    M. Sue O’Dorisio MD

Authors
  1. Daniel Calva MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas M. O’Dorisio MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Sue O’Dorisio MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Geeta Lal MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sonia Sugg MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ronald J. Weigel MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. James R. Howe MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James R. Howe MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Calva, D., O’Dorisio, T.M., Sue O’Dorisio, M. et al. When Is Prophylactic Thyroidectomy Indicated for Patients with the RET Codon 609 Mutation?. Ann Surg Oncol 16, 2237–2244 (2009). https://doi.org/10.1245/s10434-009-0524-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-009-0524-3

Keywords

Search

Navigation